When Essity hosts its Capital Markets Day in Gothenburg on May 7, 2026, the narrative won't be about incremental hygiene innovations. It will be about a decisive shift to higher-margin healthcare. The agenda—’Accelerating progress by sharpening focus and execution’—telegraphs a restructuring that could see the company prune consumer brands where it lacks pricing power, analysts say.
Essity's Medical Solutions unit, which encompasses wound care, compression therapy, and continence management, already delivers EBITDA margins north of 25%. That’s roughly 300 basis points above the group average. With organic growth in Tissue and Personal Care hovering at 2–3%, management is under pressure to reallocate resources toward segments where innovation justifies premium pricing and shields against private-label incursion.
The asset-light pivot
Speculation has mounted that Essity will exit or license certain consumer tissue brands in Europe, where market share battles with Kimberly-Clark and private labels have compressed margins. Divestment proceeds could top $1.2 billion, which the company could deploy into tuck-in acquisitions for its wound care pipeline. Recent FDA clearances for a next-generation negative pressure wound therapy device and a digital adherence tracker for compression garments highlight where R&D dollars are flowing.
We see a portfolio evolution, not a revolution, but one that can lift group ROIC by 200bps over three years.
Competitive landscape
In wound care, Essity battles Smith & Nephew, Mölnlycke, and ConvaTec. Its new NPWT system directly challenges Smith & Nephew’s PICO, which dominates the single-use segment. Meanwhile, the compression therapy market—valued at $3.5 billion—is ripe for disruption through digital monitoring. Essity’s proposed adherence platform could lock in contracts with payers seeking to reduce venous ulcer recurrence costs.
The CMD will also be a test for CEO Magnus Groth’s track record. Since the 2017 split from SCA, Essity shares have returned 18% annualized, underperforming the broader medtech index. A credible margin-expansion plan could reverse that. Markets will watch for any mention of a share buyback or dividend hike to signal confidence.
The event concludes by 13:00 CET, but the real signal will emerge in the Q&A: whether management can quantify the cost of shed assets and the timeline for medical solutions to become the majority of profits. For biotech investors, that transformation matters—it shifts Essity from a consumer staples stock to a medtech growth play, with tangible pipeline catalysts in advanced wound biologics and connected devices.
